SCHEDULE: SoftBank Entities Maintain 5.8% Stake in Roivant Sciences
Beneficial Ownership Amendment
SoftBank investment entities have disclosed a continued beneficial ownership of 5.8% in Roivant Sciences Ltd., holding over 40 million common shares.
Summary
- SB Investment Advisers (UK) Limited, SoftBank Vision Fund L.P., SVF Holdings (UK) LLP, and SVF Investments (UK) Limited collectively beneficially own 40,315,127 common shares of Roivant Sciences Ltd.
- This aggregate amount represents 5.8% of the issuer's common shares outstanding.
- The beneficial ownership is based on 690,889,856 common shares outstanding as of October 1, 2025, as disclosed in Roivant Sciences Ltd.'s Form S-3 filed on October 3, 2025.
- The reporting persons share both voting and dispositive power over all 40,315,127 shares.
- SVF Investments (UK) Limited is the record holder, with SoftBank Vision Fund L.P. managing SVF Holdings (UK) LLP, which solely owns SVF Investments (UK) Limited. SBIA UK acts as the alternative investment fund manager for SoftBank Vision Fund L.P.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by a significant institutional investor group in a biotechnology or pharmaceutical company. It reflects a continued, substantial stake by SoftBank-affiliated entities in Roivant Sciences Ltd., a company known for its 'Vant' model of developing new drug candidates.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's continued stake in the company, which can influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which requires the filing of this statement |
| 10/01/2025 | Date of common shares outstanding calculation (690,889,856 shares) |
| 10/03/2025 | Date Roivant Sciences Ltd. filed Registration Statement on Form S-3 |
| 11/14/2025 | Signature date of the Schedule 13G Amendment No. 4 filing |
Keywords
Roivant Sciences, SoftBank, Beneficial Ownership, Schedule 13G, Investment Advisers, Common Shares, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.